Partial recovery of peripheral blood monocyte subsets in head and neck squamous cell carcinoma patients upon radiotherapy is associated with decreased plasma CXCL11

• Published in: BMC cancer 2024-04, Vol.24 (1)
• Main Authors: Idel, Christian, Fleckner, Jonas, Plötze-Martin, Kirstin, Werner, Lotte, Rades, Dirk, Theodoraki, Marie-Nicole, Hofmann, Linda, Huber, Diana, Leichtle, Anke, Hoffmann, Thomas K, Bruchhage, Karl-Ludwig, Pries, Ralph
• Format: Article
• Language: English
• Subjects: Analysis; Apoptosis; Cancer; Care and treatment; Chemotherapy; Diagnosis; Head and neck cancer; Health aspects; Integrins; Patient outcomes
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/s12885-024-12177-x

Head and neck squamous cell carcinoma (HNSCC) represents a common and heterogeneous malignancy of the oral cavity, pharynx and larynx. Surgery and radio(chemo)therapy are the standard treatment options and also have great influence on the composition of the tumor microenvironment and immune cell functions. However, the impact of radio(chemo)therapy on the distribution and characteristics of circulating monocyte subsets in HNSCC are not fully understood. Expression patterns of adhesion molecules and chemokine receptors CD11a (integrin-[alpha] L; LFA-1), CD11b (integrin-[alpha] M; Mac-1), CD11c (integrin-[alpha] X), CX3CR1 (CX3CL1 receptor) and checkpoint molecule PD-L1 (programmed cell death ligand-1) were investigated upon radio(chemo)therapeutic treatment using flow cytometry. Furthermore, comprehensive analysis of plasma cytokines was performed before and after treatment using ELISA measurements. Our data reveal a partial recovery of circulating monocytes in HNSCC patients upon radio(chemo)therapeutic treatment, with differential effects of the individual therapy regimen. PD-L1 expression on non-classical monocytes significantly correlates with the individual plasma levels of chemokine CXCL11 (C-X-C motif chemokine 11). Further comprehensive investigations on larger patient cohorts are required to elucidate the meaningfulness of peripheral blood monocyte subsets and chemokine CXCL11 as potential bioliquid indicators in HNSCC with regard to therapy response and the individual immunological situation.